Published in Blood Weekly, October 31st, 2002
Under the agreement, Cangene will evaluate Gradipore's platform separation technology, Gradiflow, as an enhancement to its hyperimmune manufacturing process. During the first phase of the agreement, Gradipore will demonstrate that the Gradiflow technology can achieve strict levels of purity and recovery in an industrial setting on one of Cangene's products. The agreement specifies up-front and milestone payments by Cangene. Following the successful completion of the first phase, the companies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.